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Abstract
Objective: To define the neuropathology, clinical phenotype, autonomic physiology and differentiating features in
individuals with neuropathic and non-neuropathic postural tachycardia syndrome (POTS).
Methods:  Twenty-four  subjects  with  POTS  and  10  healthy  control  subjects  had  skin  biopsy  analysis  of  intra-
epidermal nerve fiber density (IENFD), quantitative sensory testing (QST) and autonomic testing. Subjects completed
quality  of  life,  fatigue  and  disability  questionnaires.  Subjects  were  divided  into  neuropathic  and  non-neuropathic
POTS, defined by abnormal IENFD and abnormal small fiber and sudomotor function.
Results:  Nine  of  24  subjects  had  neuropathic  POTS  and  had  significantly  lower  resting  and  tilted  heart  rates;
reduced parasympathetic function; and lower phase 4 valsalva maneuver overshoot compared with those with non-
neuropathic POTS (P<0.05). Neuropathic POTS subjects also had less anxiety and depression and greater overall
self-perceived  health-related  quality  of  life  scores  than  non-neuropathic  POTS  subjects.  A  sub-group  of  POTS
patients (cholinergic POTS) had abnormal proximal sudomotor function and symptoms that suggest gastrointestinal
and genitourinary parasympathetic nervous system dysfunction.
Conclusions and Relevance: POTS subtypes may be distinguished using small fiber and autonomic structural and
functional criteria. Patients with non-neuropathic POTS have greater anxiety, greater depression and lower health-
related  quality  of  life  scores  compared  to  those  with  neuropathic  POTS.  These  findings  suggest  different
pathophysiological processes underlie the postural tachycardia in neuropathic and non-neuropathic POTS patients.
The findings have implications for the therapeutic interventions to treat this disorder.
Citation: Gibbons CH, Bonyhay I, Benson A, Wang N, Freeman R (2013) Structural and Functional Small Fiber Abnormalities in the Neuropathic Postural
Tachycardia Syndrome. PLoS ONE 8(12): e84716. doi:10.1371/journal.pone.0084716
Editor: Pedro Gonzalez-Alegre, University of Iowa Carver College of Medicine, United States of America
Received June 17, 2013; Accepted November 26, 2013; Published December 27, 2013
Copyright: © 2013 Gibbons et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by NIH NINDS K23NS050209 (CHG) and NIH RO1 HL059459 (RF). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: rfreeman@bidmc.harvard.edu
Introduction
The  postural  orthostatic  tachycardia  syndrome  (POTS)  is
defined by an excessive increase in heart rate in the upright
position  with  associated  symptoms  of  orthostatic  intolerance
[1].  The  symptoms  of  orthostatic  intolerance  include  light-
headedness,  palpitations,  visual  blurring,  weakness,  pre-
syncope or syncope when standing. POTS is one of the most
prevalent autonomic disorders; current estimates suggest up to
500,000 patients may be affected by the disorder in the United
States alone [2].
Heterogeneous pathologies underlie POTS. Several lines of
evidence  point  to  a  restricted  peripheral  neuropathy,
specifically,  sympathetic  denervation  predominantly  in  the
lower hemibody, as a cause of POTS in some individuals. The
evidence includes reports of venous denervation [3], impaired
distal sudomotor function [4,5], lower norepinephrine spillover
in  the  legs  than  the  arms  [6],  and  the  association  with
denervation  on  skin  biopsy  [7].  This  condition  is  known  as
neuropathic  POTS.  However,  not  all  POTS  patients  have
evidence  of  a  peripheral  neuropathy.  Proposed  pathogenic
etiologies  for  non-neuropathic  POTS  include  deconditioning,
hypovolemia,  low  grade  inflammation,  oxidative  stress  and
genetic  causes  [5].  In  tertiary  referral  center  studies,  a
neuropathic  etiology  underlies  POTS  in  33  to  50%  of
individuals [6,8].
The  clinical  and  neurophysiological  differences  between
neuropathic  and  non-neuropathic  POTS  are  not  fully
elucidated.  The  objective  of  this  study  was  to  test  the
hypothesis  that  the  features  of  neuropathic  POTS  are
distinguishable from non-neuropathic POTS when assessed by
examination,  comprehensive  neurophysiologic  testing,
neuropathology  and  detailed  symptom  and  functional
questionnaires.
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Subjects
Twenty-four patients with POTS and 10 age-matched healthy
control subjects were recruited from January 2010-June 2012
for this case-control study. POTS was defined as an increase
in  heart  rate  of  >30  beats  per  minute  upon  standing  with
symptoms  of  orthostatic  intolerance,  without  any  known
medical  condition  or  medication  causing  the  tachycardia.
Screening included, but was not limited to, diabetes, impaired
glucose tolerance, vitamin deficiencies, heavily metal toxicity,
thyroid  disorders,  pheochromocytoma,  hypoadrenalism,
anxiety,  cardiac  disease,  volume  depletion,  drug  abuse  and
medication  side  effect.  Controls  were  of  similar  age  and
gender.
Protocol approvals, registrations and patient consents
Procedures  were  approved  by  the  Beth  Israel  Deaconess
Medical  Center  Institutional  Review  Board.  Written  informed
consent  was  obtained  from  all  participants  prior  to  study
participation.
Test Protocol
Individuals  participated  in  2  testing  days  separated  by  no
more  than  1  month.  On  day  1,  subjects  completed
questionnaires,  had  skin  biopsies,  quantitative  direct  and
indirect  sudomotor  testing  (QDIRT)  and  quantitative  sensory
testing (QST). On day 2, subjects underwent autonomic tests
that  included  heart  rate  variability  to  deep  breathing,  blood
pressure and heart rate response to a Valsalva maneuver and
10-minute tilt-table test.
Neurophysiologic and autonomic testing
Quantitative direct and indirect reflex testing was assessed
by iontophoresing acetylcholine solution (10%) into the skin of
the dorsum of the right foot and the distal right thigh using our
previously  reported  technique  [9].  The  sweat  droplet  number
and  area  for  both  the  direct  and  axon  reflex  regions  were
analyzed at 7-minutes post-iontophoresis. Subjects with sweat
droplet  numbers  and/or  sweat  droplet  area  below  the  5th
percentile  of  the  normative  range  at  the  foot  or  thigh  at  7-
minutes were considered abnormal.
Quantitative sensory testing
Was performed on the dorsum of the foot and included heat,
cold  and  heat-pain  perception  thresholds.  Testing  was
performed with ascending (heat and heat-pain) or descending
(cold) methods of limits using standard protocols [10]. Thermal
stimuli were applied using a 16x16 mm thermode (Medoc TSA
II  Neurosensory  Analyzer).  Patients  with  at  least  2  sensory
thresholds  below  the  5th  percentile  for  our  laboratory  were
reported as having an abnormal QST (i.e., individuals with a
single abnormal test were still considered normal).
Autonomic testing
Subjects rested in a supine position for 20 minutes prior to
testing. Blood pressures were measured non-invasively with an
automated  sphygmomanometer  (Colin  PressMate,  Colin
Medical, San Antonio, TX.). Continuous beat-to-beat finger cuff
BP  recordings  were  obtained  from  the  left  hand  (Finapres,
Ohmeda,  Englewood,  CO.).  Heart  rate  variability  to  deep
breathing, expiratory to inspiratory ratio and Valsalva maneuver
was measured as previously described [11]. The systolic blood
pressure  fall  during  phase  II  and  increase  in  phase  IV  (“the
overshoot”) of the maneuver were calculated from the beat-to-
beat BP measurements throughout the maneuver [12]. A 60°
head-up tilt was performed for 10 minutes.
Skin biopsy
Subjects  had  3mm  punch  skin  biopsies  performed  at  the
right leg 10 cm above the lateral malleolus and the right lateral
thigh 10 cm above the knee using standard techniques [13].
Specimens were fixed and stained with protein gene product
9.5 (1:1000, rabbit anti-PGP 9.5, Chemicon International Inc.)
as  previously  described  [14].  Intra-epidermal  nerve  fiber
density (IENFD) was calculated for each biopsy in a blinded
fashion using standard techniques on a florescent microscope
(Zeiss-Axioplan2, Germany) [13,15]. The presence of reduced
intra-epidermal nerve fiber density at the distal leg (<7 fibers
per  mm  –  the  5%  normative  value  cut-off  value  for
immunoflorescent  imaging  in  our  laboratory)  was  considered
abnormal.
Questionnaires
Participants  completed  the  following  questionnaires  on  the
first day of the study: the 14-point Chalder Fatigue Scale (CFS)
[16],  Hospital  Anxiety  and  Depression  Scale  [17],  Krupps
Fatigue  Severity  Scale  [18],  EuroQol-5D  (sub-dimensions
scored  as  normal  or  abnormal)  [19],  Orthostatic  Intolerance
Symptom  Assessment  [20],  Orthostatic  Intolerance  Disability
Assessment  [20]  and  the  Boston  Autonomic  Symptom
Questionnaire [21].
Definition of neuropathic POTS
Neuropathic POTS was defined as a skin biopsy below the
5th  percentile,  and  at  least  1  other  test  (quantitative  sensory
testing  or  quantitative  sudomotor  direct  and  indirect  testing)
result  below  the  5th  percentile.  All  other  subjects  were
considered ‘non-neuropathic’.
Comparison of POTS subjects with and without
sudomotor dysfunction
In  an  additional  post-hoc  analysis,  POTS  subjects  with
sudomotor  dysfunction  (defined  by  QDIRT  below  the  5th
percentile at one or more sites) were compared to those with
normal  QDIRT  function  at  both  sites  and  healthy  control
subjects.
Statistical Analysis
Statistical  analysis  was  performed  using  SPSS  17.0  (IBM
Inc. Chicago IL, USA). To avoid bias, all data were de-identified
and analyzed in a blinded fashion. Data are reported as means
± standard deviation. Baseline demographic data are analyzed
by  one-way  ANOVA  if  normally  distributed.  Neurophysiologic
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ANOVA with Tamhanes T2 post-hoc tests. Gender distribution
and EuroQol questionnaire responses are analyzed by Fisher’s
exact  test.  Other  ordinal  questionnaire  data  are  analyzed  by
Kruskal-Wallis  test  and  with  Mann-Whitney  pairwise  testing
using  Bonferroni  correction.  Relationships  between  tests  are
noted  by  Pearson  correlation  coefficient.  Significance  for  all
studies is set at p<0.05.
Results
Demographics
Twenty-four  individuals  with  POTS  (22  female)  and  10
healthy  subjects  (7  female)  participated  in  the  study.  The
distribution of defining test abnormalities is shown in Figure 1.
Nine  patients  had  neuropathic  POTS.  The  remaining  15
patients  had  non-neuropathic  POTS.  A  total  of  8  of  24
individuals  had  sudomotor  dysfunction  based  on  QDIRT
abnormalities (Figure 1).
The  subjects  with  neuropathic  POTS  were  slightly  heavier
and had a greater body mass index than individuals with non-
neuropathic  POTS  (Table  1).  There  were  no  significant
differences in height or age between groups. All male POTS
subjects  (N=2)  had  neuropathic  POTS.  There  were  no
differences in demographic characteristics between individuals
with normal and abnormal sudomotor function (Table 2).
Subjects  with  neuropathic  POTS  (per  definition)  had  lower
IENFD  than  the  non-neuropathic  POTS  group  and  controls
(p<0.05 ANOVA, both sites, Table 1). There were no IENFD
differences  between  controls  and  non-neuropathic  POTS
subjects.
Quantitative sensory testing
There were significantly higher heat and heat-pain detection
thresholds  in  the  neuropathic  POTS  group  compared  to  the
non-neuropathic and control subjects (p<0.05 ANOVA, Table
1). There were no differences in QST results between the non-
neuropathic  POTS  group  and  the  controls.  There  were  no
differences in cold detection thresholds between groups.
Autonomic testing
Resting and upright heart rate was higher in POTS subjects
than  controls.  Subjects  with  neuropathic  POTS  had  lower
resting  and  upright  heart  rates  than  non-neuropathic  POTS
subjects (Table 1). Heart rate variability to deep breathing and
Valsalva maneuver was lower in neuropathic compared to non-
neuropathic POTS subjects (table 1). Baseline blood pressures
and  phase  2  blood  pressure  responses  were  similar  in  all
groups.  The  Valsalva  phase  4  overshoot  was  lower  in
neuropathic POTS patients than controls and non-neuropathic
POTS.  Subjects  with  non-neuropathic  POTS  had  greater
Valsalva phase 4 overshoot than control subjects.
Quantitative direct and indirect reflex testing of
sudomotor function (QDIRT)
There were no differences in sweat droplet number or area
between  subjects  with  neuropathic  POTS,  non-neuropathic
POTS and control subjects at the distal leg. There was lower
Figure 1.  Distribution of test results.  Abnormal results are displayed within the lightly shaded region. The 9 individuals that meet
criteria for neuropathic POTS (abnormal skin biopsy and 1 other abnormal test) are in the darkly shaded region. A total of 9 subjects
had abnormal intra-epidermal nerve fiber density (skin biopsy). A total of 12 individuals had abnormal quantitative sensory testing
(QST). A total of 8 individuals had abnormal sudomotor (QDIRT) testing. * = individuals with neuropathic POTS, † = individuals with
cholinergic POTS.
doi: 10.1371/journal.pone.0084716.g001
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distal thigh in subjects with non-neuropathic POTS (table 1).
Correlations between tests
There were strong correlations between tests of autonomic
function  and  the  nerve  fiber  density  at  the  distal  leg.  In  all
subjects  (POTS  and  controls),  the  IENFD  at  the  distal  leg
correlated  with  the  expiratory  to  inspiratory  ratio  (r=0.61,
P<0.001) and heart rate variability to deep breathing (r=0.55,
P<0.01). In POTS subjects, IENFD at the distal leg correlated
with the expiratory to inspiratory ratio (r=0.55, P<0.05), heart
rate variability to deep breathing (r=0.63, P<0.01), the Valsalva
Table  1.  Results  for  controls,  neuropathic  and  non-
neuropathic POTS subjects.
  Control (10)  
Non-Neuropathic
POTS (15)
Neuropathic
POTS (9)
Age (years) 28±7 29±8 34±10
Height (cm) 169±7 166±5 166±13
Weight (kg) 73±14 64±6* 75±14†
Body Mass Index 25.4±3.9 23.2±2.7 27.4±4.0†
Gender 3 M 0 M 2 M
POTS Duration (years) N/A 4.9±4.4 4.4±3.5
IENFD distal leg (fibers/mm) 14.1±5.5 13.3±3.8 5.1±0.9*†
IENFD distal thigh
(fibers/mm)
16.3±5.9 16.8±4.1 8.2±1.1*†
Cold detection (°C) 29.6±1.6 28.6±2.5 29.5±1.2
Heat detection (°C) 36.1±2.81 35.3±2.8 37.9±2.4*†
Heat-pain detection (°C) 45.2±3.3 43.5±4.0 48.3±1.0*†
QDIRT number foot 63±26 54±25 49±32
QDIRT area foot 65±29 48±21 47±32
QDIRT number thigh 39±23 19±10* 30±22†
QDIRT area thigh 41±22 16±8.5* 29±25†
Exp. to Insp ratio 1.49±0.23 1.50±0.16 1.35±0.12
Max-Min heart rate (beats/
min)
23.7±11.5 28.3±7.4 19.8±5.4†
Resting heart rate (beats/
min)
59±7 71±9* 66±13
Tilt heart rate (beats/min) 89±13 124±10* 114±7†*
Supine SBP 122±15 119±11 121±10
Tilt SBP 118±13 123±13 118±11
Valsalva ratio 1.75±0.19 2.31±0.45* 1.83±0.34†
Valsalva baseline SBP
(mmHg)
119±16 121±14 120±13
Valsalva phase 2 early
blood pressure (mmHg)
107±13 108±15 108±10
Valsalva phase 2 late blood
pressure (mmHg)
121±18 120±26 124±27
Valsalva phase 4 blood
pressure (mmHg)
147±18 168±27 132±17*†
Differences  between  groups  measured  by  ANOVA  with  Tamhanes  T2  post-hoc
test  (except  gender,  Fishers  exact  test).  *=  P<0.05  vs.  Control.  †=  P<0.05
neuropathic vs. non-neuropathic. SBP: systolic blood pressure. Exp. to Insp ratio-
the expiratory to inspiratory ratio during deep breathing.
doi: 10.1371/journal.pone.0084716.t001
ratio (r=0.46, P<0.05) and the Valsalva phase 4 blood pressure
overshoot (r=0.46, P<0.05).
Questionnaires
All questionnaire results are reported in Table 3 and Figure
2. High levels of fatigue and orthostatic intolerance were seen
in patients with neuropathic and non-neuropathic POTS on the
Chalder  and  Krupps  fatigue  scales,  and  the  orthostatic
intolerance  scales.  On  the  Hospital  Anxiety  and  Depression
Scale,  subjects  with  non-neuropathic  POTS  endorsed
significantly  more  symptoms  of  depression  and  anxiety
compared  to  control  subjects.  Individuals  with  neuropathic
POTS  were  not  significantly  different  from  controls.  On  the
EuroQOL  visual  analogue  scale,  individuals  with  non-
neuropathic  POTS  reported  significantly  lower  self-perceived
overall  health-related  quality  of  life  than  neuropathic  POTS
patients  and  control  subjects.  Among  the  EuroQoL-5D  sub-
dimensions,  mobility,  ability  to  carry  out  usual  activities,  and
presence  of  pain  or  discomfort  were  greatest  in  non-
neuropathic POTS subjects (Figure 2).
Symptoms of orthostatic intolerance and orthostatic disability
were  similar  in  the  neuropathic  and  non-neuropathic  POTS
groups  and  significantly  more  than  in  the  controls  (Table  1).
There  were  no  significant  differences  among  neuropathic
Table 2. Results in individuals with normal and abnormal
sudomotor function.
  Control (10)  
Normal
sudomotor
function (16)
Abnormal
sudomotor
function (8)
Age (years) 28±7 29±9 35±9
Height (cm) 169±7 167±9 162±7
Weight (kg) 73±14 68±12 67±8
Body Mass Index 25.4±3.9 24.3±3.9 25.7±3.8
Gender 3 M 2 M 0 M
POTS Duration (years) N/A 5.4±4.1 3.4±3.7
IENFD distal leg (fibers/mm) 14.1±5.5 9.8±4.6 10.9±6.2
IENFD distal thigh (fibers/mm) 16.3±5.9 13.6±5.5 13.5±5.4
Cold detection (°C) 29.3±1.6 29.5±1.3 27.8±3.1
Heat detection (°C) 36.1±2.81 35.6±2.5 37.1±3.5
Heat-pain detection (°C) 45.2±3.3 45.0±3.7 45.9±4.8
QDIRT number foot 63±26 62±23 34±28
QDIRT area foot 65±29 56±21 33±28
QDIRT number thigh 39±23 29±16 12±8
QDIRT area thigh 41±22 26±18 12±8
Exp:Inspiratory ratio 1.49±0.23 1.46±0.17 1.43±0.15
Max-Min heart rate (beats/min) 23.7±11.5 26±8 23±7
Resting heart rate (beats/min) 60±7 70±11 69±12
Tilt heart rate (beats/min) 89±13 121±12 120±8
Supine SBP 122±15 120±12 122±11
Tilt SBP 118±13 120±11 119±12
Valsalva ratio 1.75±0.19 2.21±0.51 1.98±0.39
SBP: systolic blood pressure. Exp. to Insp ratio- the expiratory to inspiratory ratio
during deep breathing.Intra-epidermal nerve fiber density
doi: 10.1371/journal.pone.0084716.t002
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genitourinary,  cardiovascular  and  vasomotor,  autonomic
symptoms  using  the  Boston  Autonomic  Symptom
Questionnaire.
Sudomotor function analysis
IENFD,  QST  and  cardiovascular  autonomic  function  was
similar  in  individuals  with  and  without  sudomotor  dysfunction
(table  2).  Individuals  with  sudomotor  dysfunction  reported
greater difficulty with urinary flow (2.8±3.6 vs. 0.2±0.6; p<0.05),
greater incontinence (6.1±4.0 vs. 2.7±3.6; p<0.05), early satiety
(0.7±0.9 vs. 0.1±0.2; p<0.05) with more nausea and vomiting
(4.4±3.2  vs.  1.9±1.6;  p<0.05)  than  individuals  with  normal
sudomotor function.
Discussion
In this manuscript, we report the first comprehensive analysis
of  the  symptoms,  neurophysiology  and  cutaneous
neuropathology  of  individuals  with  neuropathic  and  non-
neuropathic  POTS.  The  major  findings  are:  compared  to
subjects with non-neuropathic POTS, subjects with neuropathic
POTS  have  1)  lower  resting  and  tilted  heart  rates;  2)  lower
measures  of  parasympathetic  function;  3)  lower  phase  4
Valsalva maneuver overshoot; 4) lower anxiety and depression
scores; 5) greater mobility, and greater ability to carry out usual
activities; and 6) greater self-perceived overall health related
quality  of  life.  In  addition,  we  report  a  sub-group  of  POTS
patients  with  abnormal  proximal  sudomotor  function  and
symptoms  that  suggest  gastrointestinal  and  genitourinary
parasympathetic nervous system dysfunction.
There  are  no  widely  accepted  definitions  or  diagnostic
criteria  for  neuropathic  POTS.  Previously  used  definitions
include  those  based  on  impaired  cardiovascular  autonomic
Table 3. Questionnaire Data.
Questionnaire Control (10)  
Non-neuropathic
POTS (15)
Neuropathic
POTS (9)
Chalder fatigue scale 12.5±3.7 24.2±7.2* 22.2±9.4*
Chalder physical 7.0±2.6 15.4±4.5* 14.3±6.3*
Chalder mental 5.5±1.4 9.0±3.1* 8.0±3.3*
Krupps fatigue scale 2.0±0.4 4.8±1.2* 4.1±1.5*
Orthostatic Intolerance
Symptom Assessment
1.3±1.9 28.5±14.7* 29.3±12.6*
Orthostatic Intolerance
Disability Assessment
Scale
0.5±0.8 14.3±9.6* 15.7±11.9*
Hospital Anxiety and
Depression Scale (HADS)
3.4±2.7 11.9±5.3* 9.7±8.1
HADS anxiety 1.5±1.3 5.5±2.3* 4.6±4.4
HADS depression 1.8±1.6 7.5±3.6* 5.1±4.1
Differences  between  groups  measured  by  Kruskal-Wallis  test  and  with  Mann-
Whitney pairwise testing using Bonferroni correction to define differences between
groups. *= Significant difference vs. Control.
doi: 10.1371/journal.pone.0084716.t003
function  [5],  impaired  sudomotor  function  [8],  and  impaired
distal  norepinephrine  release  [6].  Consistent  with  the  notion
that neuropathic POTS represents a distal autonomic and small
fiber  neuropathy,  our  diagnostic  criteria  included  distal  small
fiber pathology, impaired distal sensory function and impaired
distal  sudomotor  function.  We  included  impaired  sudomotor
function  in  this  definition  because  this  is  the  most  distal
autonomic function measure but excluded measures of heart
rate variability because these are more proximal measures and
seemed  likely  to  be  impaired  only  in  more  severe  cases  of
POTS. Our definition thus has a structural small fiber criterion
(intra-epidermal  nerve  fiber  density),  a  functional  small  fiber
criterion  (quantitative  sensory  testing)  and  a  functional
autonomic  criterion  (quantitative  sudomotor  function  testing).
The  differences  in  cardiac  vagal  function  between  the
neuropathic and non-neuropathic POTS groups and the strong
correlations  between  cardiac  vagal  function  measures  and
intra-epidermal  nerve  fiber  density  lends  support  to  this
classification.
The  phase  IV  overshoot  of  the  Valsalva  maneuver  was
greater in the non-neuropathic POTS subjects compared to the
control and neuropathic POTS subjects. Prior studies in both
control  [22]  and  POTS  [23]  subjects  have  shown  that  the
increased phase IV overshoot is the result of a hyperadrenergic
state. Our data suggest that the hyperadrenergic state is most
prominent  in  the  non-neuropathic  group.  Consistent  with  this
conclusion,  the  non-neuropathic  POTS  group  had  a  greater
Valsalva  ratio  compared  to  control  and  neuropathic  POTS
subjects.
The structural criterion, reduced intra-epidermal nerve fiber
density, was abnormal in 38% of POTS subjects. This differs
from  the  study  of  Singer  et  al.  in  which  none  of  8  POTS
subjects  had  intra-epidermal  nerve  fiber  densities  in  the
abnormal range, although morphological changes in the intra-
epidermal nerves were present in 3 of the 8 subjects [7]. In
contrast,  in  that  study  7  of  the  8  subjects  showed  reduced
sweating measured by QSART, and were similar to our POTS
group with sudomotor dysfunction [7].. These data lend support
to  the  lack  of  concordance  between  IENFD  and  sudomotor
function testing that was observed in our study and emphasize
the heterogeneity of the POTS population, even among those
with  evidence  of  neuropathy.  Furthermore,  our  subjects  with
neuropathic  POTS  did  not  report  any  symptoms  of  a  painful
small  fiber  neuropathy.  Although  a  number  of  disorders  are
now associated with asymptomatic small fiber neuropathy [24],
the pathophysiologic differences between individuals with and
without  symptoms  of  a  small  fiber  neuropathy  has  not  been
elucidated.  The  heterogeneity  among  subjects  suggests
different  pathophysiological  mechanisms  underlie  the  clinical
features of the disorder. The data suggest that even in those
patients in whom an immunological cause underlies the POTS,
different target nerve epitopes are likely to be implicated and
the  response  to  therapeutic  interventions  is  likely  to  differ
among phenotypes. This may underlie the challenges that exist
in treating patients with POTS.
The  POTS  cohort  had  mean  fatigue  levels  that  were
significantly different to control subjects and approached those
of chronic fatigue syndrome patients. These data confirm the
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fatigue syndrome [25-27]. A recent study drew attention to the
presence  of  deconditioning  in  POTS  patients  [28].  While  the
present data do not help disentangle the interaction between
deconditioning  and  POTS,  the  presence  of  these  levels  of
fatigue  provides  a  possible  explanation  for  the  observed
deconditioning  and  suggests  that  deconditioning  may  be
present irrespective of POTS etiology. These data, in part, may
underlie our preliminary observation that symptoms of POTS
persist despite a rigorous reconditioning exercise program [29].
Anxiety and depression were greater in POTS patients than
controls.  Furthermore,  both  anxiety  and  depression  were
greatest in non-neuropathic POTS. Similarly, overall perceived
health  status  and  the  sub-dimensions  of  mobility  and  usual
activities  tended  to  be  worse  in  non-neuropathic  POTS
patients.  Irrespective  of  etiology,  the  perceived  health  status
scores  relative  to  controls  and  neuropathic  POTS  patients
suggest  that  reduced  physical  activity  and  deconditioning  is
likely to be greater in this sub-group and implementation of a
reconditioning exercise program harder.
All non-neuropathic POTS subjects were females whereas,
22%  of  the  neuropathic  POTS  group  were  males.  Several
studies have drawn attention to the greater predisposition to
orthostatic intolerance in females compared to males [30-32].
The  physiological  factors  that  underlie  this  predisposition
include  decreased  stroke  volume  [33,34],  decreased  total
muscle sympathetic outflow [35] and differences in sympathetic
burst  discharge  characteristics  [36].  The  present  study
suggests that the gender predisposition to increased orthostatic
intolerance  may  be  particularly  applicable  to  the  non-
neuropathic POTS subgroup.
Axon-mediated  sudomotor  test  abnormalities  occurred  in
33%  of  our  POTS  cohort.  The  prevalence  of  sudomotor
abnormalities is slightly lower than prior reports in which axon-
reflex mediated sudomotor impairment was present in 43-63%
of subjects [5,8,37]. The relative difference in proportions of the
Figure 2.  Results of European Quality of Life Questionnaire.  A. The EuroQol VAS for self-perceived healthy-related quality of
life (Score of 100 = best imaginable health state, 0= worst imaginable health state). The non-neuropathic POTS had the lowest
perceived quality of life, while the neuropathic POTS subjects had lower self-perceived health than control subjects. * p< 0.01 vs.
controls, † p<0.01 vs. neuropathic POTS (ANOVA with Tamhanes T2 post-hoc test).
The EuroQol 5D (B) shows the individual sub-dimensions with the percent of individuals reporting abnormalities shown. Significant
differences in mobility, usual activities and pain were noted between groups (*=P<0.05, Fishers exact test). A greater percent of
non-neuropathic POTS subjects reported self-perceived difficulty across all sub-dimensions than control and neuropathic POTS
subjects (with the exception of anxiety which was reported with the same frequency as neuropathic POTS subjects).
doi: 10.1371/journal.pone.0084716.g002
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respective centers.
The  sudomotor  abnormalities  in  our  POTS  cohort  did  not
have a distal to proximal gradient. Similar observations have
been  made  by  other  investigators  studying  thermoregulatory
and axon-mediated sweating in POTS. Thieben et al. observed
a regional or mixed pattern in 20% of patients [8], Peltier et al.
reported  patchy  sudomotor  abnormalities  [37]  while  Khurana
observed  predominantly  upper  limb  anhidrosis  in  50%  of
subjects [38].
Sudomotor  abnormalities  in  our  cohort  occurred  less
frequently  than  intra-epidermal  nerve  fiber  density
abnormalities  and  QST  abnormalities.  In  contrast,  QSART
dysfunction  was  the  most  common  abnormality  in  the
autonomic  neuropathy  cohort  of  Sheklee  et  al.  occurring  in
63% of subjects [5]. In that cohort, gastrointestinal symptoms
such  as  abdominal  pain,  bloating,  nausea  and  constipation
occurred in almost 70% of subjects. Their cohort has features
in common with our POTS subjects with sudomotor dysfunction
in  which  gastrointestinal  symptoms  such  as  early  satiety,
nausea  and  vomiting  occurred.  In  our  POTS  subjects  with
sudomotor  dysfunction,  urinary  flow  and  urinary  incontinence
also occurred more frequently in this POTS subgroup raising
the possibility of a generalized dysfunction of the cholinergic
system.
These POTS patients with sudomotor dysfunction bear some
similarity to post-ganglionic cholinergic dysautonomia which is
characterized by generalized, post-ganglionic parasympathetic
nervous system impairment that includes gastrointestinal and
bladder  dysfunction,  pupillomotor  deficits,  sudomotor
dysfunction, xerophthalmia and xerostomia [39-43]. Compared
to reported cases of post-ganglionic cholinergic dysautonomia,
the parasympathetic impairment in this POTS subgroup was,
as expected, less prominent. But the prevalence in our series is
similar  to  previously  reported  series  on  idiopathic  autonomic
neuropathy in which 20%[44] to 26%[45] of subjects presented
with pure cholinergic dysautonomia.
The cholinergic POTS subgroup is therefore consistent with
the hypothesis that neuropathic POTS is a restricted autonomic
neuropathy  [6].  Post-ganglionic  cholinergic  dysautonomia  is
frequently associated with a viral infection and is most likely
immune-mediated  [6,39-45].  The  absence  of  a  distal  to
proximal gradient in sudomotor deficits, observed by us and by
others  lends  additional  support  to  the  possibility  that  an
immune-mediated  process  underlies  neuropathic  POTS
[5,8,37].  Taken  together,  these  data  provide  support  for
heterogeneity even among neuropathic POTS subgroups.
The  cause  of  the  exaggerated  postural  tachycardia  in  the
cholinergic  dysautonomic  group  is  not  immediately  apparent.
While impaired cardiac vagal function could provide a possible
pathophysiological explanation, heart rate variability with deep
respiration  and  the  heart  rate  response  to  a  Valsalva
maneuver, measures of cardiac vagal function, were similar to
the control subjects in this group. Alternatively, there could be
impaired  selective  distal  vasomotor  denervation  but  this  was
not evaluated in this study.
There are limitations to our study. The POTS patients were
recruited  at  a  tertiary-care  center  with  a  special  interest  in
peripheral neuropathy. The numbers are small and the relative
proportions of neuropathic and non-neuropathic POTS patients
cannot be generalized to the general population. The concept
of  cholinergic  POTS  is  based  on  a  post-hoc  analysis.  This
should  be  examined  prospectively  in  future  studies.
Nevertheless,  the  study  demonstrates  that  there  are  several
POTS subgroups with coherent symptoms, and structural and
functional features. These findings may have implications for
the natural history of POTS and the response of POTS patients
to therapeutic interventions.
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